Enterprise AI is no longer a future ambition. It is in full operational flight. Model capabilities are advancing faster than most organizations can absorb, while the cost of performance continues to fall. Globally, AI investment is set to reach $2.5 trillion in 2026, up 44% from the previous year. For many enterprises, this investment has…
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.